Maternal serum SHARP1 and hypoxia inducible factor-1α as biomarkers for preeclampsia | ||||
| Evidence Based Women's Health Journal | ||||
| Article 48, Volume 12, Issue 4, November 2022, Page 311-318 PDF (429.19 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ebwhj.2022.158984.1196 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mahmoud Hassan  1; Nancy Rund2; Nehal Moussa3; Mahmoud Moussa4
| ||||
| 1Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt | ||||
| 2Professor in Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Consultant of Obstetrics and Gynecology at Bugshan Hospital, Jeddah, Saudi Arabia. | ||||
| 3Laboratory Department, Ministry of Interior Hospitals, Cairo, Egypt | ||||
| 4Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Department of Obstetrics and Gynecology, Great Western Hospital, Swindon, UK | ||||
| Abstract | ||||
| Objectives: Preeclampsia remains a major cause of maternal mortality and morbidity worldwide, with an increased risk of cardiovascular disease later in life. Many previous studies have examined several biomarkers. We aimed to assess the role of Split and hairy-related protein-1 (SHARP1) together with hypoxia-inducible factor-1α (HIF-1α) as biomarkers for the detection of preeclampsia. Materials and Methods: This case-control study included 150 pregnant women, 75 healthy women and 75 with preeclampsia, who were recruited for delivery during the third trimester of pregnancy and subjected to full clinical and laboratory testing. This testing included compete blood analysis, and plasma SHARP1 and HIF-1α measurement using ELISA. The main outcome was the association of SHARP1 and HIF-1α with preeclampsia. Results: A significant decrease in SHARP1 (P < 0.0001) and a significant increase in HIF-1α (P < 0.0001) were observed in patients versus the controls. The SHARP1 and HIF-1α levels were independent indicators of preeclampsia after adjusting for maternal age, body mass index, and parity (the odds ratio for SHARP1 was 0.04, 95% confidence interval 0.321–0.791; P < 0.0001, and the OR for HIF-1α was 30.222, 95% CI 6.219 – 146.877; P < 0.0001). Conclusion: SHARP1 and HIF-1α may have be used as biomarkers for the proper recognition of preeclampsia. The synergistic actions of SHARP1 and HIF-1α might play a key role in the pathogenesis of preeclampsia. Larger studies are likely to help verify the data and justify the wider application of these markers. | ||||
| Keywords | ||||
| Hypoxia inducible factor-1α; preeclampsia; SHARP1 | ||||
|
Statistics Article View: 145 PDF Download: 175 |
||||
